Literature DB >> 3865878

Incidence of severe sideeffects during therapy with sulfonylureas and biguanides.

W Berger.   

Abstract

The most important side-effect of sulfonylureas is hypoglycaemia. According to surveys in Switzerland and in Sweden it occurs at a frequency of about 2 cases per 10,000 treatment years. Mortality is high, about 10%. The syndrome of inappropriate ADH-secretion has been observed almost exclusively during treatment with chlorpropamide. Asymptomatic cases of SIADH-syndrome are quite frequent, hyponatraemia has been observed in 6-10% of diabetics treated with chlorpropamide. The most dangerous side-effect of biguanides is lactic acidosis. It occurs significantly more frequent during treatment with phenformin compared to metformin. Metformin has been reported to lead to lactic acidosis in 0.4 cases per 10,000 treatment years; mortality is about 30%. Mortality of phenformin-associated lactic acidosis is even higher, 70%. Both biguanides, phenformin and metformin, cause relatively frequently vitamin B12-malabsorption (in about 1/3 of the cases). However, symptomatic vitamin B12-deficiency is extremely rare.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3865878

Source DB:  PubMed          Journal:  Horm Metab Res Suppl        ISSN: 0170-5903


  19 in total

Review 1.  [Value of biguanide in therapy of diabetes mellitus].

Authors:  E Haupt; U Panten
Journal:  Med Klin (Munich)       Date:  1997-08-15

2.  Inverse association between glucose-lowering medications and severe hyponatremia: a Swedish population-based case-control study.

Authors:  Henrik Falhammar; Jakob Skov; Jan Calissendorff; Jonatan D Lindh; Buster Mannheimer
Journal:  Endocrine       Date:  2019-12-25       Impact factor: 3.633

Review 3.  A risk-benefit assessment of metformin in type 2 diabetes mellitus.

Authors:  H C Howlett; C J Bailey
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

4.  Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

Authors:  B H Wolffenbuttel; L Nijst; J P Sels; P P Menheere; P G Müller; A C Kruseman
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.

Authors:  C R Culy; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  The effect of glibenclamide on insulin secretion at normal glucose concentrations.

Authors:  Axel Riefflin; Usha Ayyagari; Susan E Manley; Rury R Holman; Jonathan C Levy
Journal:  Diabetologia       Date:  2014-10-09       Impact factor: 10.122

Review 7.  The management of diabetes mellitus in older individuals.

Authors:  J E Morley; H M Perry
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

Review 8.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention.

Authors:  Aruna Chelliah; Mark R Burge
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Comparative tolerability profiles of oral antidiabetic agents.

Authors:  A J Krentz; R E Ferner; C J Bailey
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.